Q

    Quest Diagnostics Incorporated (DGX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $240.29
    -2.47 (-1.02%)

    Market Cap: $26.79B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    95%(38/40)
    Avg Surprise
    +5.09%
    Streak
    30 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$2.86
    Range$2.82 - $2.91
    13 analysts
    EPS Revisions
    11
    0
    7d
    11
    1
    30d
    EPS Estimate Drift
    90d ago$2.80-2.1%
    60d ago$2.80-2.2%
    30d ago$2.80-2.2%
    7d ago$2.85-0.5%
    Current$2.86
    Revenue Consensus
    $3.0B
    Range$3.0B - $3.1B
    11 analysts
    Dec 31, 2026
    EPS Consensus$3.14
    Range$3.07 - $3.44
    16 analysts
    Revenue Consensus
    $3.2B
    Range$3.0B - $3.3B
    15 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.14---
    Sep 26EST
    		-$2.86---
    Jun 26
    		$3.12$2.81+11.03%Beat+19.1%
    Mar 26
    		$2.50$2.37+5.49%Beat+13.1%
    Dec 25
    		$2.42$2.36+2.54%Beat+8.5%
    Sep 25
    		$2.60$2.50+4.00%Beat+13.0%
    Jun 25
    		$2.62$2.57+1.95%Beat+11.5%
    Mar 25
    		$2.21$2.15+2.79%Beat+8.3%
    Dec 24
    		$2.23$2.18+2.29%Beat+3.7%
    Sep 24
    		$2.30$2.26+1.77%Beat+3.6%
    Jun 24
    		$2.35$2.33+0.86%Beat+2.2%
    Mar 24
    		$2.04$1.86+9.68%Beat+0.0%
    Dec 23
    		$2.15$2.11+1.90%Beat+8.6%
    Sep 23
    		$2.22$2.19+1.37%Beat-5.9%
    Jun 23
    		$2.30$2.26+1.77%Beat-2.5%
    Mar 23
    		$2.04$1.97+3.55%Beat-36.6%
    Dec 22
    		$1.98$1.90+4.21%Beat-40.5%
    Sep 22
    		$2.36$2.19+7.76%Beat-40.4%
    Jun 22
    		$2.36$2.27+3.96%Beat-25.8%
    Mar 22
    		$3.22$3.00+7.33%Beat-14.4%
    Dec 21
    		$3.33$3.21+3.74%Beat-25.7%
    Sep 21
    		$3.96$3.06+29.41%Beat-8.1%
    Jun 21
    		$3.18$2.86+11.19%Beat+123.9%
    Mar 21
    		$3.76$3.73+0.80%Beat+300.0%
    Dec 20
    		$4.48$4.24+5.66%Beat+168.3%
    Sep 20
    		$4.31$3.73+15.55%Beat+144.9%
    Jun 20
    		$1.42$1.25+13.60%Beat-17.9%
    Mar 20
    		$0.94$0.88+6.82%Beat-32.9%
    Dec 19
    		$1.67$1.60+4.38%Beat+22.8%
    Sep 19
    		$1.76$1.71+2.92%Beat+4.8%
    Jun 19
    		$1.73$1.68+2.98%Beat-1.1%
    Mar 19
    		$1.40$1.38+1.45%Beat-7.9%
    Dec 18
    		$1.36$1.37-0.73%Miss-2.9%
    Sep 18
    		$1.68$1.68+0.00%Beat+20.9%
    Jun 18
    		$1.75$1.76-0.57%Miss+12.9%
    Mar 18
    		$1.52$1.50+1.33%Beat+14.3%
    Dec 17
    		$1.40$1.37+2.19%Beat+6.9%
    Sep 17
    		$1.39$1.36+2.21%Beat+1.5%
    Jun 17
    		$1.55$1.42+9.15%Beat-
    Mar 17
    		$1.33$1.18+12.71%Beat-
    Dec 16
    		$1.31$1.27+3.15%Beat-
    Sep 16
    		$1.37$1.35+1.48%Beat-

    Dividends

    Dividend Metrics

    Yield1.38%
    Annual/Share$3.32
    Payout Ratio19.37%
    Frequency4
    Pay MonthsJan, Apr, Jul, Oct

    Growth

    3Y CAGR+6.61%
    5Y CAGR+7.35%
    View DGX's full dividend history

    Key Metrics

    Valuation
    P/E Ratio22.58EV/EBITDA14.54x
    Price/FCF19.77xFCF Yield5.06%
    Profitability
    Profit Margin9.19%Operating Margin15.20%
    ROE14.60%ROIC9.74%
    Financial Health
    Debt/Equity0.75xInterest Coverage7.35x
    Current Ratio1.59xQuick Ratio1.46x
    Trading Statistics
    Beta0.55Avg Volume805.18K
    52-Week High$247.1952-Week Low$168.97

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$242.47
    SMA 20$239.50
    SMA 50$224.28
    SMA 200$199.09
    EMA 10$241.75
    EMA 20$238.32
    EMA 50$226.95
    EMA 200$203.62

    MACD

    Line: 5.34Signal: 6.13Hist: -0.80

    ADX

    ADX: 38.8+DI: 25.2-DI: 14.0

    Aroon & PSAR

    Aroon Up92.0
    Aroon DownN/A
    PSAR$234.86

    Bollinger Bands

    Upper Band$247.01
    Lower Band$231.99
    %B Position627%(Upper)
    Band Width0.55

    RSI (14-Day)

    Neutral
    60.7

    Momentum Oscillators

    Stoch %K68.9
    Stoch %D79.7
    Williams %R-46.3
    ROC (10d)2.0%
    Momentum4.77
    CCI (20d)29.5
    MFI (14d)53.9

    Volatility Measures

    ATR (14d)$4.74(2.0%)
    StdDev (20d)3.76
    Hist Vol12.8%(Low)

    Volume Flow

    VWAP$240.78
    OBV5.3M
    AD Line-276.9M
    CMF (20d)0.108

    Volume Metrics

    Avg Vol (20d)803.5K
    Vol Ratio1.6x(High)
    VWMA (20d)$239.91

    Pivot Points

    R3$247.61
    R2$246.45
    R1$244.60
    Pivot Point$243.44
    S1$241.59
    S2$240.43
    S3$238.58

    Advanced Oscillators

    TSI40.60
    Ultimate Osc54.1
    KST87.89

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.04B$2.90B$2.81B$2.82B$2.76B$2.65B$2.62B$2.49B$2.40B$2.37B$2.29B$2.29B
    Cost of Revenue$2.02B$1.95B$1.90B$1.87B$1.82B$1.79B$1.76B$1.68B$1.59B$1.59B$1.55B$1.54B
    Gross Profit$1.03B$942.00M$910.00M$949.00M$943.00M$863.00M$858.00M$811.00M$804.00M$771.00M$736.00M$754.00M
    Operating Expenses$568.00M$543.00M$524.00M$563.00M$505.00M$517.00M$497.00M$481.00M$449.00M$471.00M$469.00M$412.00M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$529.00M$504.00M$504.00M$501.00M$486.00M$476.00M$466.00M$448.00M$416.00M$440.00M$407.00M$380.00M
    Operating Income$459.00M$399.00M$386.00M$386.00M$438.00M$346.00M$361.00M$330.00M$355.00M$300.00M$267.00M$342.00M
    Interest Income$-63,000,000$-63,000,000$-64,000,000$-66,000,000$-67,000,000$-67,000,000$-65,000,000$-49,000,000$-44,000,000$-43,000,000$0$-40,000,000
    Interest Expense$47.00M$65.00M$56.00M$58.00M$54.00M$70.00M$62.00M$34.00M$41.00M$34.00M$30.00M$43.00M
    Income Before Tax$412.00M$334.00M$330.00M$328.00M$384.00M$276.00M$299.00M$296.00M$314.00M$266.00M$237.00M$299.00M
    Income Tax Expense$88.00M$74.00M$81.00M$77.00M$97.00M$59.00M$68.00M$65.00M$74.00M$66.00M$40.00M$68.00M
    Net Income$334.00M$264.00M$256.00M$259.00M$296.00M$235.00M$236.00M$237.00M$240.00M$208.00M$205.00M$237.00M
    EBITDA$621.00M$544.00M$539.00M$536.00M$594.00M$483.00M$499.00M$470.00M$475.00M$425.00M$386.00M$450.00M
    EBIT$475.00M$397.00M$394.00M$394.00M$451.00M$343.00M$364.00M$345.00M$358.00M$309.00M$277.00M$339.00M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DGX

    Government Contracts

    Gov Obligations (TTM)
    $66.92M
    Gov Obligations / Revenue
    0.6%
    Obligations YoY
    5.7%
    Active Awards
    727
    New Awards (TTM)
    434
    Avg Remaining Term
    5.2 mo

    Top agency: Department of Veterans Affairs at 95.0% of trailing twelve month obligations across 3 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24726N0012Department of Veterans AffairsDepartment of Veterans Affairs$8.25MOct 1, 2025
    36C24726P0300Department of Veterans AffairsDepartment of Veterans Affairs$4.70MApr 1, 2026
    36C25226N0362Department of Veterans AffairsDepartment of Veterans Affairs$3.12MApr 1, 2026
    36C25226N0110Department of Veterans AffairsDepartment of Veterans Affairs$3.03MOct 1, 2025
    36C24826N0124Department of Veterans AffairsDepartment of Veterans Affairs$2.75MNov 1, 2025
    36C24626N0574Department of Veterans AffairsDepartment of Veterans Affairs$2.71MApr 1, 2026
    36C24826N0043Department of Veterans AffairsDepartment of Veterans Affairs$2.70MOct 1, 2025
    36C24526F0012Department of Veterans AffairsDepartment of Veterans Affairs$2.69MOct 1, 2025
    36C25226N0411Department of Veterans AffairsDepartment of Veterans Affairs$2.60MMay 1, 2026
    36C25726N0235Department of Veterans AffairsDepartment of Veterans Affairs$2.57MMay 1, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Quest Diagnostics stock holds steady as investors weigh latest quarterly trends

    Quest Diagnostics stock is trading steadily in late August 2026 as investors evaluate its latest quarterly trends and the overall demand for diagnostic testing. The company's recent interim report showed billions in quarterly revenue, an increase from the previous year, with stable operating margins despite rising costs. Investors are looking at the company's full-year guidance for 2026, which projects low- to mid-single-digit revenue growth and mid-single-digit adjusted earnings per share growth, to determine its future stock performance.

    AD HOC NEWS•8/29/26•
    Somewhat-Bullish

    Quest Diagnostics (NYSE: DGX) holder to sell 22,677 shares

    Michael E. Prevoznik, a holder of Quest Diagnostics (DGX), plans to sell 22,677 shares of common stock through Fidelity Brokerage Services LLC. This sale, stemming from a stock option exercise, is scheduled for August 28, 2026, on the NYSE, with an aggregate market value of $5,513,082.35. The filing indicates a neutral impact and sentiment on the company's stock.

    Stock Titan•8/28/26•
    Neutral

    Back-to-school health checklist: What parents can do to help kids start the school year strong

    As the new school year approaches, parents are advised to prioritize their children's health by scheduling physicals and vaccinations early. MinuteClinic providers emphasize the importance of preparedness for common illnesses and reinforcing healthy habits at home, such as frequent handwashing and adequate sleep. Convenient care options like MinuteClinic appointments and virtual visits are available to help busy families manage their children's health needs.

    CVS Health•8/26/26•
    Neutral

    Quest Diagnostics brings a $29 biological-age report to the U.S.—no extra blood draw

    Quest Diagnostics has partnered with Humanity Health to offer a $29 Biological Age analysis as an add-on to select health profile tests purchased through questhealth.com in the U.S. This allows customers to receive a report estimating their biological age and its contributing factors without an additional blood draw, using existing lab results. The service, developed with Imperial College London and validated on over 306,000 UK Biobank participants, is now available in five countries, aiming to empower individuals with insights for proactive health management.

    Stock Titan•8/25/26•
    Somewhat-Bullish

    Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology

    Quest Diagnostics is expanding its Quest AD-Detect® portfolio with two new offerings to improve Alzheimer's disease diagnosis. The company will introduce an FDA-cleared Roche pTau217 blood test in Q4 2026 and launch a new multi-biomarker AD-Detect® lab-developed blood test with a low 10% indeterminate rate by the end of August. These advancements aim to broaden access to quality blood tests for symptomatic patients, building on Quest's commitment to innovation in Alzheimer's diagnostics.

    Sahm•8/24/26•
    Neutral

    Frequently Asked Questions About DGX

    What is DGX's current dividend yield?
    Quest Diagnostics Incorporated (DGX) has a current dividend yield of 1.38%.
    Does DGX pay dividends?
    Yes, Quest Diagnostics Incorporated pays dividends with a current yield of 1.38%.
    What is DGX's P/E ratio?
    Quest Diagnostics Incorporated has a price-to-earnings (P/E) ratio of 22.58.
    What is DGX's market cap?
    Quest Diagnostics Incorporated (DGX) has a market capitalization of $26.79B with a current stock price of $240.29.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In